EDMONTON, Alberta, Nov. 2 /PRNewswire-FirstCall/ -- Medical Services International Inc. is pleased to announce that it has obtained the exclusive marketing and distribution rights to a confirming test kit for Tuberculosis (TB). This kit is registered with the FDA in the United States. The VScan TB test kit is used as a preliminary screening test to detect the presence of active TB in an individual. Once TB has been detected there are several follow up tests necessary to confirm the Tuberculosis (TB) and begin treatment. The test kit that Medical Services has received the rights to is used to complete the additional testing required if the VScan TB test gives a positive result.
This FDA registered diagnostic test kit is designed to be used for the rapid identification of infectious human diseases and identifies 34 disease producing bacteria, including Tuberculosis (TB), Mycobacterium avium- intracellulare (MAI), Pseudomonas and Nocardia. These bacteria are also cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis and AIDS. This test kit combined with the VScan TB test allows for the rapid detection and verification of Tuberculosis (TB). These kits when used in conjunction with each other allow for the early detection and treatment of TB at a fraction of the cost and time required using conventional methods. In addition to the cost and time saved the combination of the two tests are much more accurate that conventional methods.
TB is the number one killer of people with HIV/AIDS. It is projected by WHO that TB will kill over 8.0 million people this year. TB will kill more people this year than all other infectious diseases combined. TB is very infectious. With early diagnosis, most TB is treatable.
The addition of the new test kit to the VScan product line increases the value of the VScan TB test kit significantly. It reduces the cost and time previously needed for diagnosis of TB and makes it easier for individuals to be tested.
About VScan
The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV 1&2. Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Malaria, Syphilis, and Prostate Cancer. The kits cannot be sold in Canada.
Medical Services International Inc. trades in the United States on the NQB Pinksheets under the symbol “MSITF”. For further information, please contact Robert Talbot at (780) 430 6363 or media contact Bill Whitehead at (416) 822 5883 or http://www.medicalservicesintl.com or http://www.minerva-biotech.com .
NOTE: Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and filings with regulatory bodies.
Medical Services International Inc.
CONTACT: Robert Talbot, +1-780-430-6363, or media contact, Bill Whitehead,+1-416-822-5883, both for Medical Services International Inc.